Protara Therapeutics Inc (TARA) earnings · next report Nov 9, 2026
Next report
Mon, Nov 9, 2026
Time not announced · In 5 days
Quarter ended Sep 2026
- EPS consensus
- −$0.37 Range −$0.38 – −$0.346 analystsYear ago −$0.31
- Revenue consensus
- $0 Range $0 – $06 analysts
EPS estimate trend
- 90 days ago−$0.33
- 60 days ago−$0.36
- 30 days ago−$0.36
- 7 days ago−$0.36
- Now−$0.36
Consensus −9.7% over 90 days. Last 30 days: 0 up, 3 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow TARA into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 9)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±2.9% Absolute close-to-close move, 2 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.36
vs −$0.33 est. −9.1%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 2 of 4
- Aug 11, 2026MissEPS −$0.36GAAP vs −$0.33 −9.1%Rev — vs —
- May 13, 2026BeatEPS −$0.31GAAP vs −$0.37 +16.2%Rev — vs —
- Mar 10, 2026MissEPS −$0.38GAAP vs −$0.31 −21.8%Rev — vs —
- Nov 10, 2025BeatEPS −$0.31GAAP vs −$0.38 +18.4%Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Jun 2026 | −$0.33 | −$0.36GAAP | −9.1% | — | — | — |
| May 13, 2026 | Mar 2026 | −$0.37 | −$0.31GAAP | +16.2% | — | — | — |
| Mar 10, 2026 | Dec 2025 | −$0.31 | −$0.38GAAP | −21.8% | — | — | — |
| Nov 10, 2025 | Sep 2025 | −$0.38 | −$0.31GAAP | +18.4% | — | — | — |
Earnings documents
- Earnings press releaseEX-99.1 · 8-K filed Aug 11, 2026Open on SEC.gov
Read the filing on LicianEDGAR filing index
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
TARA is rated 1.47 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- SMMT earnings1.52 · Sell · stock
- MLYS earnings1.49 · Strong Sell · stock
- ABEO earnings1.48 · Strong Sell · stock
- CLPT earnings1.48 · Strong Sell · stock
- BNTC earnings1.46 · Strong Sell · stock
- ENTA earnings1.45 · Strong Sell · stock
- NVAX earnings1.45 · Strong Sell · stock
- FHTX earnings1.44 · Strong Sell · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.36 | — |
| Q1 FY26 | — | −$0.31 | — |
| Q3 FY25 | — | −$0.31 | — |
| Q2 FY25 | — | −$0.35 | — |
Protara Therapeutics Inc (TARA) is a biotechnology company listed on NASDAQ.
No cached income statement for TARA yet, so there is no earnings base to recap.
When the next TARA 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
Period-over-period revenue change is not in cache for TARA. We will not invent a beat or miss.
Not investment advice. Full TARA research stays on the stock page; the tape stays on the quote page.
TARA earnings FAQ
When is TARA's next earnings date?
Protara Therapeutics Inc (TARA) is expected to report on Mon, Nov 9, 2026. This is the provider’s estimated date; the company has not confirmed it. Consensus EPS is −$0.37.
Did TARA beat earnings estimates last quarter?
No. On Aug 11, 2026 Protara Therapeutics Inc (TARA) reported adjusted EPS of −$0.36 against a −$0.33 consensus (−9.1%), a miss.
How often does TARA beat EPS estimates?
Protara Therapeutics Inc (TARA) beat the EPS consensus in 8 of its last 11 reported quarters.
Not investment advice.